Open-label, single center, phase I trial to investigate the mass balance and absolute bioavailability of the oral c-Met inhibitor tepotinib

被引：0
|
作者：
Johne, A. [1 ]
Scheible, H. [2 ]
Becker, A. [1 ]
Van Lier, J. J. [3 ]
Meyring, M. [2 ]
机构：
[1] Merck KGaA, Global Early Dev, Darmstadt, Germany
[2] Merck KGaA, Inst Drug Metab & Pharmacokinet, Grafing, Germany
[3] Pharmaceut Res Assoc, Early Dev Serv, Zuidlaren, Netherlands
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30232-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
369
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [31] Absolute Bioavailability of Esaxerenone and Food Effects on its Pharmacokinetics After a Single Oral Dose in Healthy Japanese Subjects: An Open-Label Crossover Study
    Kurata, Akifumi
    Furuie, Hidetoshi
    Ishizuka, Tomoko
    Nakatsu, Takafumi
    Shimizu, Takako
    Kato, Manabu
    Nishikawa, Yasuhiro
    Ishizuka, Hitoshi
    ADVANCES IN THERAPY, 2019, 36 (07) : 1618 - 1627
  • [32] Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours
    Tanja Trarbach
    Beate Schultheis
    Thomas C. Gauler
    Vesile Schneider
    Dirk Strumberg
    Wilfried E. E. Eberhardt
    Stephanie Le Scouiller
    Marcelo Marotti
    Kathryn H. Brown
    Joachim Drevs
    Investigational New Drugs, 2012, 30 : 1962 - 1971
  • [33] Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours
    Trarbach, Tanja
    Schultheis, Beate
    Gauler, Thomas C.
    Schneider, Vesile
    Strumberg, Dirk
    Eberhardt, Wilfried E. E.
    Le Scouiller, Stephanie
    Marotti, Marcelo
    Brown, Kathryn H.
    Drevs, Joachim
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (05) : 1962 - 1971
  • [34] Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single-center, open-label phase I trial
    Deng, Kunhong
    Zou, Yi
    Zou, Chan
    Wang, Hong
    Xiang, Yuxia
    Yang, Xiaoyan
    Yang, Shuang
    Cui, Chang
    Yang, Guoping
    Huang, Jie
    CANCER MEDICINE, 2023, 12 (02): : 1431 - 1440
  • [35] A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
    Evens, Andrew M.
    Balasubramanian, Sriram
    Vose, Julie M.
    Harb, Wael
    Gordon, Leo I.
    Langdon, Robert
    Sprague, Julian
    Sirisawad, Mint
    Mani, Chitra
    Yue, Jeanne
    Luan, Ying
    Horton, Sharon
    Graef, Thorsten
    Bartlett, Nancy L.
    CLINICAL CANCER RESEARCH, 2016, 22 (05) : 1059 - 1066
  • [36] PATIENT SATISFACTION WITH ORAL TESTOSTERONE UNDECANOATE (JATENZO) IN MEN WITH PREVIOUS TESTOSTERONE THERAPY: AN OPEN-LABEL SINGLE-CENTER PHASE IV CLINICAL TRIAL
    Rivero, M.
    Reddy, R.
    Patel, M.
    Muthigi, A.
    Ramasamy, R.
    JOURNAL OF SEXUAL MEDICINE, 2023, 20
  • [37] AN OPEN-LABEL, TWO-PART, SEQUENTIAL DOSE STUDY ASSESSING THE ABSOLUTE BIOAVAILABILITY, MASS BALANCE, AND RECOVERY FOR [14C]-ROSIPTOR (AQX-1125) IN HEALTHY SUBJECTS
    Tam, Patrick
    Scholl, Dorothea
    Toews, Judy
    Harwig, Curtis
    Mackenzie, Lloyd F.
    JOURNAL OF UROLOGY, 2018, 199 (04): : E515 - E515
  • [38] Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial
    Urwyler, Pascal
    Leimbacher, Marina
    Charitos, Panteleimon
    Moser, Stephan
    Heijnen, Ingmar A. F. M.
    Trendelenburg, Marten
    Thoma, Reto
    Sumer, Johannes
    Camacho-Ortiz, Adrian
    Bacci, Marcelo R.
    Huber, Lars C.
    Stussi-Helbling, Melina
    Albrich, Werner C.
    Sendi, Parham
    Osthoff, Michael
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [39] A First in Class, Open-Label, First-in-Human, Phase I Trial of Daily Oral Pclx-001
    Sangha, Randeep
    Sehn, Laurie H.
    Jamal, Rahima
    Spratlin, Jennifer
    Kuruvilla, John
    Weickert, Michael J.
    Berthiaume, Luc G.
    Mackey, John R.
    BLOOD, 2022, 140 : 12057 - 12058
  • [40] A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension
    Li, Yan
    Liu, Liangang
    Huang, Lian
    Wang, Xiaomin
    Hoffmann, Matthew
    Reyes, Josephine
    Palmisano, Maria
    Zhou, Simon
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2018, 10 : 1089 - 1099
12345